Follicular Lymphoma | Clinical

Zandelisib Moves Along in Development for B- Cell Malignancies

August 12, 2021

The first patient with marginal zone lymphoma has been dosed in the global phase 2 TIDAL study of zandelisib, a phosphatidylinositol 3-kinase (PI3K) delta inhibitor, for the treatment of MZL and follicular lymphoma in patients who have received at least 2 or more prior therapies.